Agios Recruits Rare Disease Leader Brian Goff As CEO To Execute Commercial Transition

Leadership change comes after CEO Jackie Fouse, who will serve as board chair, oversaw the sale of Agios' cancer portfolio, a reorganization and a shift in therapeutic focus to rare diseases.

chess piece representing a leader
Agios appointed a new CEO Brian Goff • Source: Shutterstock

The stars aligned for Agios Pharmaceuticals, Inc. to bring former Alexion Pharmaceuticals Inc. commercial head Brian Goff on board as CEO to oversee the launch of the company's first rare disease drug, Pyrukynd (mitapivat), according to CEO Jackie Fouse, who will hand the leadership reins to Goff in August.

Agios announced the leadership transition after market close on 12 July, with Fouse stepping into the role of board chair...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from Scrip